6 completed, 3 recruiting, 2 active not recruiting, 2 withdrawn. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 6, Recruiting 3, Active not recruiting 2, Withdrawn 2, Terminated 1 |
| Phase 2 | 6 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1 |
Follow Folotyn: new trials by email Literature Review of Folotyn trials Research Report on Folotyn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-25 | 2026-10-29 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) Pralatrexate Injection - Peripheral T-Cell Lymphoma (PTCL) | Phase 1 | Completed | Acrotech Biopharma Inc. | 48 | 2015-11-10 | 2021-07-27 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Pralatrexate, Romidepsin - Lymphoid Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 57 | 2013-09-09 | 2026-09-16 |
| Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® Folotyn, Fusilev - Non-Small Cell Lung Cancer | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-04-01 | 2020-01-23 | |
| Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Fusilev, Folotyn - Non Hodgkin's Lymphoma | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-03-01 | 2020-01-23 | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies Erlotinib, Pralatrexate - Advanced Cancers, Solid Tumors | Phase 1 | Completed | M.D. Anderson Cancer Center | 72 | 2012-03-01 | 2016-07-04 |
| Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Nebraska | 29 | 2010-09-14 | 2023-12-26 |
| Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Pralatrexate Injection, Bexarotene Capsules, Vitamin B12 - Cutaneous T-cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | Acrotech Biopharma Inc. | 34 | 2010-03-01 | 2019-12-18 |
| Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12 - Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 119 | 2007-05-01 | 2020-01-07 |
| 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma pralatrexate - Lymphoma | Phase 1 / Phase 2 | Completed | Spectrum Pharmaceuticals, Inc | 72 | 2002-08-01 | 2021-08-25 |
Lymphoma, T-Cell (6) · Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Lymphoma (3) · Lymphoma, Follicular (3) · Lymphoma, T-Cell, Peripheral (3) · Burkitt Lymphoma (2) · Enteropathy-Associated T-Cell Lymphoma (2) · Immunoblastic Lymphadenopathy (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Recurrence (2)
Acrotech Biopharma Inc. (5) · City of Hope Medical Center (2) · University of Virginia (2) · Fred Hutchinson Cancer Center (1) · Jennifer Amengual (1) · M.D. Anderson Cancer Center (1) · Spectrum Pharmaceuticals, Inc (1) · University of Nebraska (1)
United States (12) · Italy (1)
Ahmed Sawas, MD (1) · Alex F Herrera (1) · Christina Poh (1) · Enrica Marchi, M.D., PhD (1) · Enrica Marchi, MD, PhD (1) · Erard Gilles, MD (1) · Jean Grem (1) · Jennifer Amengual, MD (1) · Lorenzo Iovino, MD, PhD (1) · Michael Saunders, MD (1) · Owen A. O'Connor, MD, PhD (1) · Owen O'Connor, MD, PhD (1) · Pankaj Sharma, MD (1) · Shumei Kato, MD (1)
PMID 19652067, PMID 26242208, PMID 29141948, PMID 38029357, PMID 38517235
P30CA033572 (1)